Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsColorado, Georgia
Drug(s) in Trial Other Drug Names Main Known Action
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
MethoxyamineTRC102Base excision repair inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT02576444IIAdvanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutationsA Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid TumorsView DrugsConnecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02832167IIAdvanced solid tumorsAn Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic MalignanciesView DrugsArizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02873962IIPlatinum resistant or partially sensitive ovarian cancerA Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT02571725IIRecurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerView DrugsFlorida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityView DrugsNew Jersey
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03462342IIRecurrent ovarian cancerCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT01876511IIAdvanced solid tumors with positive MSI or tumors with negative MSI and high TMBPhase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) TumorsView DrugsCalifornia, Maryland, New York, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsView DrugsFlorida, Maryland, Michigan, Missouri, New York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03579316IIRecurrent ovarian cancer (PD on or after prior PARP inhibitor)A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionView DrugsMassachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune response
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerView DrugsCalifornia, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03693014IIAdvanced solid tumors with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingView DrugsCalifornia, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
RintatolimodAtvogen, AmpligenTLR-3 agonist and immune cell stimulator
NCT03673124IIRecurrent low grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or PeritoneumView DrugsFlorida, Georgia, Illinois, Indiana, New Mexico, Oklahoma, Pennsylvania, Rhode Island, Texas
Drug(s) in Trial Other Drug Names Main Known Action
LetrozoleFemaraAromatase inhibitor
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitor
NCT03742895IIAdvanced BRCA1/2-wild type solid tumors with DNA repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced CancerView DrugsCalifornia, Georgia, Kentucky, Maryland, Massachusetts, Michigan, Nebraska, New Jersey, New York, Oklahoma, Pennsylvania, South Dakota, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03834220IIAdvanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusionA Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3View DrugsArizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Oklahoma, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Debiopharm 1347FGFR Inhibitor Debio 1347, FF284, CH5183284, Debio 1347FGFR1-3 inhibitor
NCT03836352IIRecurrent ovarian cancer (with tumor lesions < 5 cm)A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.View DrugsFlorida, Louisiana, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
BrigatinibAP26113ALK and EGFR kinase inhibitor
NCT03697304IIAdvanced solid tumors with prior PD-1/PD-L1 targeted treatmentAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyView DrugsCalifornia, Florida, Indiana, Kentucky, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 754111Blocks LAG-3 inhibition of T cells
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®View DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
2X-121PARP inhibitor
NCT02819843IIAdvanced solid tumors - intratumoral injectionA Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
Talimogene LaherparepvecGM-CSF-encoding oncolytic herpes simplex virus, T-VECInduces immune response and tumor cell lysis
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
Onapristone ERextended-release onapristonePR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsView DrugsKentucky
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03824704IIRecurrent carcinosarcoma, high grade serous or endometrioid ovarian cancerA Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)View DrugsCalifornia, Georgia, Louisiana, Oklahoma, Vermont
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid TumorsView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
CapecitabineCAPE, XelodaRNA processing and thymidylate synthase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02710253IIAdvanced solid tumors (amenable to radiation therapy) - with progression on systemic immunotherapyPhase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
NCT03449108IIRecurrent high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
LN-145autologous TILs LN-145, autologous tumor infiltrating lymphocytes LN-145Anti-tumor immune response
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesView DrugsIdaho, Iowa, Massachusetts, Michigan, Montana, New York, Ohio, Oregon, Pennsylvania, Vermont, Virginia, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
EntrectinibTrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101ALK, TRK, ROS1 kinase inhibitor
GDC-0084RG7666, PI3K inhibitor GDC-0084PI3K/mTOR inhibitor
NCT03993379IIAdvanced solid tumorsA Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsView DrugsIdaho, Illinois, Oregon, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
CX-072protease-activated anti-PD-L1 antibody prodrug CX-072Blocks PD-L1 inhibition of T cells
NCT03872427IIAdvanced solid tumors with NF1, KEAP1/NRF2 or LKB1 mutationsA Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant TumorsView DrugsContact NCI
Drug(s) in Trial Other Drug Names Main Known Action
Telaglenastatglutaminase inhibitor CB-839, CD-839Glutaminase inhibitor
NCT04082572IIAdvanced solid tumors with loss of MLH1, PMS2, MSH2 or MSH6 or with high MSINeoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid CancersView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT04083976IIAdvanced solid tumors with a FGFR mutation or gene fusionA Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene AlterationsView DrugsMaine, New Jersey, New York, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitor
NCT04098068IIAdvanced solid tumors with high TMB and low MSIPhase 2 Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) TumorsView DrugsMaryland, Massachusetts, New York, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT04034927IIPlatinum sensitive high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancerA Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerView DrugsContact NCI
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03861403Ib/IIaAdvanced solid tumors (inc ovarian expansion)A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsView DrugsIndiana, New York, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
TRX518anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518GITR (glucocorticoid-induced TNFR) agonist
NCT04042116Ib/IIAdvanced solid tumors (inc expansion)A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With an Advanced, Metastatic Solid TumorView DrugsFlorida, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03717415Ib/IIAdvanced solid tumorsAn Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsView DrugsCalifornia, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitor
NCT03330405Ib/IIPlatinum sensitive recurrent ovarian cancerA Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid TumorsView DrugsArkansas, California, District of Columbia, Massachusetts, Michigan, Minnesota, New York, Ohio, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT02759588Ib/IIPlatinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)View DrugsCalifornia, Florida
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
GL-ONC1light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68Membrane disrupter
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02785250Ib/IIRecurrent ovarian cancerA Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian CancerView DrugsCalifornia, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
NCT02994953IbAdvanced solid tumorsA Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonist
NCT02761694IbAdvanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion)A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN MutationsView DrugsOklahoma, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
ARQ 751pan-AKT inhibitor ARQ 751Akt inhibitor
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03150810IbAdvanced solid tumors (inc ovarian expansion)A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsMichigan, Missouri, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PamiparibPARP inhibitor BGB-290PARP inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT03113188IbAdvanced solid tumorsPhase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory TumorsView DrugsArizona, Louisiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action
CBP501G2 checkpoint inhibitor CBP501G2 checkpoint inhibitor
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GalunisertibLY2157299TGFBR1 antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03307785IbAdvanced solid tumorsPhase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerView DrugsArizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DostarlimabANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042Blocks PD-L1/2 inhibition of T cells
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TSR-022Blocks TIM-3 inhibition of T cells
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03695380IbPlatinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion)A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian CancerView DrugsArizona, California, Florida, Georgia, Maryland, Missouri, New York, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03650348IbAdvanced HER2+ solid tumors (inc expansion)A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsView DrugsCalifornia, Louisiana, New York, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsView DrugsCalifornia, Connecticut, Florida, Illinois, New Jersey, New York, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO1 to stimulate immune response
INCB050465PI3K-delta inhibitor INCB050465PI3K delta inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT03872947IbPlatinum sensitive or partially sensitive ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsView DrugsArizona, California, Louisiana, New Jersey, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
TRK-950monoclonal antibody TRK-950Undisclosed mechanism
NCT03842228IbAdvanced solid tumors (inc expansion)A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid TumorsView DrugsContact NCI
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03514121Ia/IbAdvanced solid tumors (in ovarian expansion)A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid TumorsView DrugsArizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
FPA150anti-B7-H4 monoclonal antibody FPA150Blocks B7-H4 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03209401Ia/IbAdvanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesView DrugsDistrict of Columbia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
NCT02913313I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsPennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986207anti-TIGIT monoclonal antibody BMS-986207Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02754141I/IIaAdvanced solid tumorsA Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid TumorsView DrugsConnecticut, Illinois, Maryland, Massachusetts, New York, Oklahoma, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986179anti-CD73 monoclonal antibody BMS-986179Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03110107I/IIaAdvanced solid tumors (in expansion)Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsColorado, Massachusetts, Nevada, New Jersey, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986218Blocks CTLA-4 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02650986I/IIaAdvanced solid tumors (inc expansion)A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced MalignanciesView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1
TGFbeta DNRII-transduced Autologous Tumor Infiltrating LymphocytesTGFbeta Dominant Negative Receptor II transduced TILSTGFbeta ligand trap
NCT02111850I/IIAdvanced MAGE-3+ solid tumorsPhase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and AldesleukinView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
Anti-MAGE-A3-DP4 TCR PBLHLA-DP0401/0402-restricted, MAGE-A3-reactive T cell receptor-transduced autologous T cellsImmune response against cancer expressing MAGE-3
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NCT02953457I/IIRecurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or high LOH/HRD scoresA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02432378I/IIPlatinum sensitive ovarian cancer with first recurrence in peritoneal cavity - intranodal injection (inc expansion)A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 VaccinesView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Alpha-DC1 vaccineAnti-tumor immune response
CelecoxibCelebrex
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
NCT02671435I/IIAdvanced solid tumorsA Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid TumorsView DrugsAlabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
MonalizumabIPH2201, anti-NKG2A monoclonal antibody IPH2201Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytes
NCT02484404I/IIRecurrent ovarian cancerPhase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
CediranibAZD2171, Cediranib maleate, RecentinVEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02487095I/IIExtrapulmonary small cell ovarian cancerA Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibM6620, VE-822, ATR kinase inhibitor VX-970, ATR kinase inhibitor VX-970ATR kinase inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT02734004I/IIPlatinum sensitive recurrent ovarian cancerA Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid TumorsView DrugsGeorgia, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03251924I/IIAdvanced solid tumorsA Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsView DrugsDistrict of Columbia, Massachusetts, Missouri, New Jersey, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986226anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226Stimulates ICOS to increase T cell activity and immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03314935I/IIAdvanced solid tumorsA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid TumorsView DrugsAlabama, California, Georgia, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
INCB001158CB-1158, Arginase inhibitorArginase inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03446040I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant TumorsView DrugsCalifornia, Colorado, Connecticut, Michigan, New Hampshire, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986258anti-TIM3 antibody BMS-986258Blocks TIM-3 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03369223I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsColorado, Florida, Maryland, New Jersey, New York, Ohio, Oregon, Pennsylvania, South Carolina, Texas, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986249Probody of ipilumumabBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03386526I/IIAdvanced solid tumorsA Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
APG-138SM-138SMAC mimetic and IAP antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03400332I/IIAdvanced solid tumorsA Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced CancersView DrugsColorado, Florida, Maryland, Nevada, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986253IL-8 antagonist
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03407976I/IIAdvanced solid tumors with high MSI or dMMRA Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)View DrugsUtah
Drug(s) in Trial Other Drug Names Main Known Action
ApatinibYN968D1, Aitan, ATAN, Rivoceranibc-Met/VEGFR2 kinase inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03721679I/IIAdvanced solid cancersPoly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot StudyView DrugsMaryland, New York
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
poly ICLCpoly-ICLC, Hiltonol, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, poly I:poly C with poly-1-lysine stabilizerActivates dendritic cells and induces interferon production
NCT03775850I/IIAdvanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapyA Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsView DrugsFlorida, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
EDP1503monoclonal microbial EDP1503
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03744468I/IIAdvanced solid tumorsPhase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsView DrugsColorado, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BGB-A425Blocks TIM-3 inhibition of T cells
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cells
NCT03729596I/IIAdvanced solid tumorsA Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid TumorsView DrugsMichigan, North Carolina, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
MGC018A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payloadADC: anti-B7-H3 + DNA alkylating agent (duocarmycin)
NCT03157128I/IIAdvanced solid tumorsA Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)View DrugsArizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
LOXO-292RET kinase inhibitor LOXO-292RET-kinase inhibitor
NCT03665285I/IIAdvanced solid tumorsA Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, New Jersey, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
NC318anti-S15 monoclonal antibody NC318, anti-Siglec-15 monoclonal antibody NC318Blocks tumor-associated macrophage stimulation of tumor growth
NCT03459222I/IIAdvanced solid tumorsA Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsView DrugsCalifornia, Colorado, Maryland, Missouri, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986205Inhibits IDO1 to stimulate immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cells
NCT03761914I/IIRecurrent or persistent WT1+ ovarian cancerA Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced CancersView DrugsCalifornia, Florida, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Galinpepimut-SImmune response against cancer expressing WT1
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03767348I/IIAdvanced solid tumor - intratumoral injection (in expansion)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsView DrugsArizona, Connecticut, Florida, Kentucky, New Jersey, New York, Oregon, Tennessee, Texas, Utah, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysis
NCT03840200I/IIRecurrent ovarian cancerA Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate CancerView DrugsCalifornia, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03907852I/IIAdvanced mesothelin+ solid tumors (inc ovarian expansion)A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing CancerView DrugsMaryland, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
TC-210 T cellsTC-210 TruC-T cellsImmune response against cancer expressing mesothelin
NCT04021043I/IIAdvanced solid tumors (inc expansion)Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986156GITR (glucocorticoid-induced TNFR) agonist
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03997968I/IIAdvanced solid tumors (inc expansion)A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid TumorsView DrugsColorado, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
CYT-0851RAD51 inhibitor
NCT03992131I/IIAdvanced solid tumors (inc ovarian expansion)SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid TumorView DrugsMassachusetts, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
LucitanibVEGFR/FGFR dual kinase inhibitor E-3810VEGFR and FGFR kinase inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
Sacituzumab Govitecananti-TROP-2 Antibody-Drug Conjugate IMMU-132, hrS7-SN38 antibody drug conjugateADC: Anti-TROP2 + topoisomerase I inhibitor
NCT03994601I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant TumorsView DrugsColorado, Maryland, Missouri, New Jersey
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986288Undisclosed mechanism
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT04068194I/IIAdvanced solid tumorsA Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesView DrugsContact NCI
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
M3814DNA-PK inhibitor MSC2490484A, NedisertibDNA-PK inhibitor
Radiation TherapyRadiotherapy, Irradiation
NCT03138083I/IIAdvanced solid tumors with MET alterationsA Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
OMO-1MET kinase inhibitor OMO-1, JNJ-38877618c-Met kinase inhibitor
NCT04104776I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid TumorsView DrugsMichigan, New Jersey, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CPI-0209EZH2 histone methyltransferase inhibitor
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitor
NCT03711058I/IIAdvanced solid tumors with low MSIA Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03785249I/IIAdvanced solid tumors with KRAS G12C mutation (inc expansion)A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C MutationView DrugsCalifornia, Massachusetts, Michigan, New York, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
MRTX849KRAS G12C inhibitor MRTX849KRAS G12C inhibitor
NCT03884556I/IbAdvanced solid tumors (inc expansion)Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor MalignanciesView DrugsFlorida, Tennessee, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
TTX-030anti-CD39 monoclonal antibodyInhibits the breakdown of ATP by CD39
NCT02660034I/IbPlatinum sensitive or partially sensitive ovarian cancer (at least 2 prior platinum therapies, in expansion)A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid TumorsView DrugsArizona, California, Colorado, Florida, Massachusetts, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
PamiparibPARP inhibitor BGB-290PARP inhibitor
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cells
NCT03511222IAdvanced solid tumors with high MSIA Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid TumorsView DrugsMissouri
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
VorolanibCM-082, X-82VEGFR and PDGFR kinase inhibitor
NCT01417546IAdvanced solid tumors (in expansion)First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid TumorsView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonist
NCT03435250IAdvanced solid tumors with CDKN2A deletion (inc expansion)A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAPView DrugsConnecticut, Massachusetts, New York, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AG-270Methionine adenosyltransferase 2a (MAT2A) inhibitor
NCT02675439IAdvanced solid tumors - intratumoral injectionA Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or LymphomasView DrugsColorado, Illinois, Massachusetts, New York, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action
ADU-S100CDN agonist ADU-S100, MIW815, STING-activating cyclic dinucleotide agonist ADU-S100Activates STING to stimulate immune cell activation
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NCT03059823IAdvanced solid tumors (inc expansion)A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid TumorsView DrugsArizona, Michigan, New Jersey, North Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT03431948IAdvanced solid tumors (amenable to radiation therapy)Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid TumorsView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
UrelumabBMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibodyStimulates 4-1BB (CD137) to increase T cells and immune response
NCT03335540IAdvanced solid tumorsADaptiVe Biomarker Trial That InformS Evolution of TherapyView DrugsIllinois, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986205Inhibits IDO1 to stimulate immune response
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitor
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cells
NCT03144661IRecurrent advanced serous ovarian cancerA Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesView DrugsAlabama, New York
Drug(s) in Trial Other Drug Names Main Known Action
INCB062079FGFR4 inhibitor
NCT03154294IAdvanced solid tumorsA Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid TumorsView DrugsSouth Dakota
Drug(s) in Trial Other Drug Names Main Known Action
MLN1117INK-1117, TAK-117, PI3K alpha inhibitor MLN1117, SerabelisibPI3K alpha inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
SapanisertibINK128, TORC1/2 Inhibitor INK128, TORC1/2 Inhibitor MLN0128, MLN0128, TAK-228TORC1/2 kinase inhibitor
NCT03213964IRecurrent advanced ovarian cancer only in abdomen/pelvisIntraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
FATE-NK100NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100Anti-tumor immune response
NCT03319459IAdvanced solid tumors, including HER2+ or EGFR+ tumorsFATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsView DrugsCalifornia, Minnesota, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
FATE-NK100NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100Anti-tumor immune response
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonist
NCT03310541IAdvanced solid tumors with AKT1, AKT2, or AKT3 mutationsA Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3View DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
NCT02715284IAdvanced solid tumors (inc expansion)A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid TumorsView DrugsAlabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maine, Massachusetts, Michigan, Missouri, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
DostarlimabANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042Blocks PD-L1/2 inhibition of T cells
NCT03313778IAdvanced solid tumors with high MSI or high TMB (in expansion)A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid TumorsView DrugsFlorida, Massachusetts, New Jersey, New York, North Carolina, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
mRNA-4157mRNA-based personalized cancer vaccine mRNA-4157Anti-tumor immune response
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT02611024IAdvanced solid tumors (inc expansion)Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitor
LurbinectedinPM01183
NCT03192345IAdvanced solid tumorsA Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid TumorsView DrugsCalifornia, Kansas, Massachusetts, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Cemiplimabanti-PD-1 monoclonal antibody REGN2810, anti-PD-1 monoclonal antibody REGN2810Blocks PD-L1/2 inhibition of T cells
SAR439459anti-TGF-beta monoclonal antibody SAR-439459TGFbeta antagonist
NCT02937272IAdvanced solid tumors (inc expansion)A Phase 1 Study of LY3200882 in Patients With Solid TumorsView DrugsCalifornia, Kentucky, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
LY3200882TGFbeta inhibitor LY3200882, TGFb inhibitor LY 3200882TGFbeta antagonist
LY3300054Blocks PD-L1 inhibition of T cells
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
NCT03289962IAdvanced solid tumorsA Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic TumorsView DrugsArizona, California, Colorado, Connecticut, District of Columbia, Massachusetts, Nevada, New York, Oklahoma, Oregon, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
RO7198457personalized cancer vaccine RO7198457, PCV RO7198457Immune response against tumor-associated antigens
NCT03229278IAdvanced solid tumors with high MSIA Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesView DrugsNew Jersey
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
TrigriluzoleBHV-4157, FC-4157Glutamate antagonist
NCT01434316IAdvanced solid tumors including those with BRCA1/2 mutations (in expansion)Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
DinaciclibSCH 727965, CDK inhibitor SCH 727965CDK1, 2, 5, 9 inhibitor
VeliparibABT-888PARP inhibitor
NCT02503774IAdvanced solid tumors (in expansion)A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsView DrugsCalifornia, Connecticut, Florida, Georgia, Missouri, North Carolina, Ohio, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Oleclumabanti-CD73 monoclonal antibody MEDI9447Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
NCT02627443IPlatinum sensitive ovarian cancer at first or second recurrencePhase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerView DrugsArizona, Florida, Kentucky, Minnesota, Missouri, Pennsylvania, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibM6620, VE-822, ATR kinase inhibitor VX-970, ATR kinase inhibitor VX-970ATR kinase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
NCT02433626IRecurrent ovarian cancerA Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
COTI-2mutant p53 activator COTI-2Mutant p53 activator
NCT02534922IRecurrent or persistent ovarian cancerPhase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerView DrugsSouth Carolina
Drug(s) in Trial Other Drug Names Main Known Action
ProlantaProlactin receptor antagonist
NCT02791334IAdvanced solid tumors (in expansion)A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)View DrugsTennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
LY3300054Blocks PD-L1 inhibition of T cells
LY3321367anti-TIM3 monoclonal antibody LY3321367Blocks TIM-3 inhibition of T cells
Ramucirumabanti-VEGFR-2 fully human monoclonal antibody IMC-1121B, IMC-1121B, LY3009806VEGFR2 antagonist
NCT02897375IAdvanced solid tumorsA Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid MalignanciesView DrugsGeorgia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
NCT01376505IAdvanced solid tumors (in ovarian expansion)Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid TumorsView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccineImmune response against cancer expressing HER2
NCT02498912IMUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies)A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid TumorsView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytesImmune response against cancer expressing CA125
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NCT02829723IAdvanced solid tumorsA Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid TumorsView DrugsTennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BLZ945CSF-1R inhibitor BLZ945CSF1R antagonist and tumor-associated macrophage inhibitor
Spartalizumabanti-PD-1 monoclonal antibody PDR001, PDR001Blocks PD-L1/2 inhibition of T cells
NCT03017131IRecurrent or refractory ovarian cancerA Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian CancerView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
Decitabine5-aza-dCyd, deoxyazacytidine, dezocitidine, DacogenDNA methylation inhibitor
Genetically Engineered NY-ESO-1-specific T LymphocytesImmune response against cancer expressing NY-ESO-1
NCT03030378IAdvanced solid tumorsA Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid TumorsView DrugsCalifornia, Colorado, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
IL-12cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12IL-12 receptor agonist
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT02972034IAdvanced solid tumorsA Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced MalignanciesView DrugsMichigan, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
MK-8353ERK1 inhibitor MK-8353ERK inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03069469IAdvanced solid tumors (in expansion)Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced TumorsView DrugsCalifornia, Colorado, Florida, New York, Oregon, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
DCC-3014CSF1R kinase inhibitor
NCT03018405IAdvanced solid tumors (in expansion)A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)View DrugsFlorida, New York
Drug(s) in Trial Other Drug Names Main Known Action
NKR-2autologous NKG2D CAR-CD3zeta-DAP10-expressing T lymphocytes CYAD-01Immune response against cancer expressing NKG2D-L
NCT03054298IRecurrent or persistent mesothelin+ serous ovarian cancerPhase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
Hu-CART-meso cellsImmune response against cancer expressing mesothelin
NCT03154281IAdvanced ovarian cancer (no prior PARPi)A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast CancerView DrugsSouth Dakota
Drug(s) in Trial Other Drug Names Main Known Action
EverolimusAfinitor, Certican, RAD001, ZortressmTOR inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03056833IPlatinum sensitive recurrent ovarian cancerPhase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitor
NCT03023319IAdvanced solid tumorsPhase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
BosutinibBosulif, SKI-606Abl and src family kinase inhibitor
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitor
NCT03894540IAdvanced solid tumors (inc expansion)A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid TumoursView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
IPN60090Undisclosed mechanism
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03893955IAdvanced solid tumorsA Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsAlabama, California, Connecticut, North Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
ABBV-368Stimulates OX40 to increase T cell activation and immune response
ABBV-927anti-CD40 agonist monoclonal antibody ABBV-927Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response
NCT03628677IAdvanced solid tumors (inc expansion)A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesView DrugsCalifornia, North Carolina, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AB122anti-PD-1 monoclonal antibody AB122Blocks PD-L1 inhibition of T cells
AB154Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NCT03920839IAdvanced solid tumors at first recurrenceA Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)View DrugsCalifornia, Delaware
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitor
NCT02743637IAdvanced solid tumorsA Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid TumorsView DrugsArizona, California, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
SDX-7320methionine aminopeptidase type II inhibitor SDX-7320, MetAP2 inhibitor SDX-7320Angiogenesis inhibitor
NCT03934814IAdvanced solid tumors (inc ovarian expansion)A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and LymphomaView DrugsAlabama, Arizona, California, Connecticut, Florida, Indiana, Michigan, Minnesota, New York, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
TJ011133TJC4Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT03946800IAdvanced solid tumors (inc expansion) - intratumoral injectionA Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid TumorsView DrugsArizona, California, Illinois, New York, Rhode Island, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
MEDI1191IL-12 mRNA, lipid nanoparticle encapsulating mRNA encoding human IL-12IL-12 receptor agonist
NCT03956680IAdvanced solid tumors - optional intratumoral injectionA Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid CancersView DrugsIllinois, Maryland, Missouri, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986301differentiated STING agonist, Small molecule STING agonistActivates STING to stimulate immune cell activation
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03444714IAdvanced solid tumors (with lesion amenable to palliative radiation therapy) - intratumoral injectionPhase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced TumorsView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
RiMO-301MOF compound RiMO-301, metal-organic framework (MOF) compound RiMO-301Induces ROS-mediated DNA damage (following intratumoral injection and radiation)
NCT03423628IAdvanced solid tumors with brain metastases not eligible for Stereotactic Radiosurgery (SRS) treatmentA Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid TumorsView DrugsMassachusetts, New York, Pennsylvania, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
AZD1390brain-penetrant ATM inhibitor AZD1390ATM kinase inhibitor
Radiation TherapyRadiotherapy, Irradiation
NCT03925428IAdvanced solid tumorsPhase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and LymphomasView DrugsContact NCI
Drug(s) in Trial Other Drug Names Main Known Action
EntinostatHDAC inhibitor SNDX-275, MS 275, SNDX-275HDAC inhibitor
MolibresibBET inhibitor GSK525762, I-BET762BET inhibitor
NCT03928314IAdvanced solid tumors (inc expansion)An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid TumorsView DrugsCalifornia, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
ORIC-101GR antagonist
NCT03240861IAdvanced NY-ESO-1+ solid tumorsAdoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
BusulfanBusulfex, busulphan, CB-2041, Glyzophrol, GT-41, joacamine, leucosulfan, mielucin, misulban, misulfan, mitosan, myeleukon, myeloleukon, myelosan, mylecytan, myleran, sulfabutin, WR-19508DNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NY-ESO-1 TCR transgenic T cells and NY-ESO-1 TCR/sr39TK transgenic stem cellsImmune response against cancer expressing NY-ESO-1
NCT03841110IAdvanced solid tumors (inc expansion)FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)View DrugsCalifornia, Minnesota, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
FT500Anti-tumor immune response
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03849469IAdvanced solid tumors (inc expansion)A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)View DrugsGeorgia, Michigan, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
XmAb22841anti-CTLA-4/LAG-3 bispecific antibody XmAb22841Blocks LAG-3 and CTLA-4 inhibition of T cells
NCT03861793IAdvanced solid tumors (inc expansion)A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)View DrugsGeorgia, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action
ALKS 4230IL-2 receptor agonist
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03556228IAdvanced solid tumors (inc expansion)An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or LymphomaView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
VMD-928TrkA inhibitor VMD-928TRK kinase inhibitor
NCT03831295IAdvanced solid tumors - intratumoral injectionIntratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]View DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986178anti-OX40 antibody BMS 986178Stimulates OX40 to increase T cell activation and immune response
SD-101TLR9 agonist SD-101, ISS-ODN SD-101TLR9 agonist and immune cell activator
NCT03821935IAdvanced solid tumorsA Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsConnecticut, Indiana, North Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action
ABBV-151ARGX-115binds GARP in complex with inactive TGF-beta preventing release of active TGF-beta
ABBV-181anti-PD1 monoclonal antibody ABBV-181Blocks PD-L1 inhibition of T cells
NCT03875287IAdvanced solid tumorsA Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid TumorsView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
ASTX727CDA inhibitor E7727/decitabine combination agent ASTX727DNA methylation inhibitor
NCT03156114IAdvanced solid tumors with high MSI or high TMB and prior checkpoint inhibitor treatment (in expansion)An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid TumorsView DrugsFlorida, New Jersey, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 754111Blocks LAG-3 inhibition of T cells
NCT02990481IAdvanced solid tumors (in expansion)A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid TumorsView DrugsArizona
Drug(s) in Trial Other Drug Names Main Known Action
TRK-950monoclonal antibody TRK-950Undisclosed mechanism
NCT03132922IAdvanced MAGE-A4+, HLA-A1+ solid tumorsPhase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive TumorsView DrugsFlorida, Missouri, New York, North Carolina, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
MAGE-A4ᶜ¹º³²TMAGE-A4 SPEAR, engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4)Immune response against cancer expressing MAGE-A4
NCT03748186IRecurrent ovarian cancer (inc expansion)A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC) in Advanced Epithelial Ovarian Cancer and Endometrial CancersView DrugsColorado, Florida, Illinois, Nevada, North Carolina, Pennsylvania, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
STRO-002ADC: anti-FOLR1 + microtubule destabilizer (SC209)
NCT03538028IAdvanced solid tumors (inc expansion)A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced MalignanciesView DrugsCalifornia, New Jersey, North Carolina, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
INCAGN02385Blocks LAG-3 inhibition of T cells
NCT03134638IAdvanced solid tumors (in ovarian expansion)A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid TumorsView DrugsAlabama, Arizona, California, Illinois, Massachusetts, New York, Oklahoma, Oregon, Rhode Island, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
SY-1365CDK7 inhibitor SY-1365, SY 1365CDK7 inihibitor
NCT03517956IAdvanced solid tumors with FGFR over-expressionA Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid TumorsView DrugsCalifornia, Illinois, Maryland, Massachusetts, Michigan, Nevada, New York, South Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
Rogaratinibpan-FGFR tyrosine kinase inhibitor BAY1163877, BAY1163877pan-FGFR kinase inhibitor
NCT03255070IAdvanced HER+ solid tumorsA Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 ExpressionView DrugsMissouri
Drug(s) in Trial Other Drug Names Main Known Action
ARX788anti-HER2 antibody-drug conjugate ARX788, ADC ARX788ADC: anti-HER2 + microtubule destabilizer (MMAF)
NCT03330561IAdvanced HER2+ solid tumors (inc expansion)A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid TumorsView DrugsArizona, California, District of Columbia, Maryland, New York, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2
NCT03585764IRecurrent or persistent FRalpha+ high grade serous ovarian cancerPhase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
MOv19-BBz CAR TImmune response against cancer expressing folate receptor
NCT03486301IAdvanced solid tumors (inc expansion)Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsView DrugsFlorida, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BDB001TLR agonist and immune cell stimulator
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03665129IAdvanced solid tumorsA Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid TumorsView DrugsTennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
IPH5401Blocks C5aR mediated inhibition of T and NK cells
NCT03691376IRecurrent or refractory NY-ESO-1+ ovarian cancerA Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
MelphalanSarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustardDNA damaging agent
NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC)Immune response against cancer expressing NY-ESO-1
NY-ESO-1 CD8-TCR Engineered T CellsImmune response against cancer expressing NY-ESO-1
NCT03502733IAdvanced solid tumorsPhase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and LymphomasView DrugsMaryland, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03099109IAdvanced solid tumors (inc expansion)A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid TumorsView DrugsArizona, Massachusetts, Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
LY3300054Blocks PD-L1 inhibition of T cells
LY3321367anti-TIM3 monoclonal antibody LY3321367Blocks TIM-3 inhibition of T cells
NCT02516813IOvarian cancer with an indication for palliative radiation therapyAn Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid TumorsView DrugsFlorida, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
M3814DNA-PK inhibitor MSC2490484A, NedisertibDNA-PK inhibitor
NCT03739931IAdvanced solid tumors (inc expansion) - intratumoral injectionA Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint BlockadeView DrugsColorado, Connecticut, Florida, Michigan, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
mRNA-2752lipid nanoparticle-encapsulated OX40L, IL23, IL36gamma mRNA-2752
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03139370IAdvanced MAGE-A3/A6+, HLA-DPB1*04:01+ (inc expansion)A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced CancersView DrugsCalifornia, Florida, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
KITE-718MAGEA3/A6-targeted TCR-transduced T cells KITE-718, autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718immune response against cancer expressing MAGE-A3/A6
NCT03724890IAdvanced solid tumorsA Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid TumorsView DrugsCalifornia, Florida, Illinois, New York, Ohio, Oklahoma, South Carolina, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
M3814DNA-PK inhibitor MSC2490484A, NedisertibDNA-PK inhibitor
Radiation TherapyRadiotherapy, Irradiation
NCT03725436IAdvanced solid tumors that are TP53 WTA Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
ALRN-6924MDM2/MDMX inhibitor ALRN-6924MDM2 and MDMX inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03719326IAdvanced ovarian cancer (inc expansion)A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic MalignanciesView DrugsArizona, California, Colorado, Florida, Maryland, Minnesota, Nevada, New York, North Carolina, Oregon, Texas, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AB928AB928, a dual antagonist of the A2aR and A2bR adenosine receptorsBlocks adenosine A2A/B receptors inhibition of T cells
IPI-549PI3K-gamma inhibitor IPI-549PI3K gamma inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
NCT04087018IAdvanced solid tumors with high TMB or positive Strata Immune SignatureA Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid TumorsView DrugsWisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AB122anti-PD-1 monoclonal antibody AB122Blocks PD-L1 inhibition of T cells
NCT04088786IPatients with peritoneal disease who are candidates for grossly complete cytoreduction surgeryPhase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface MalignanciesView DrugsCalifornia, Kentucky, New York
Drug(s) in Trial Other Drug Names Main Known Action
Liposomal irinotecanOnivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecanTopoisomerase I inhibitor
NCT04092270IRecurrent ovarian cancer (inc expansion)A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Ovarian Cancer With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)View DrugsContact NCI
Drug(s) in Trial Other Drug Names Main Known Action
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
M3814DNA-PK inhibitor MSC2490484A, NedisertibDNA-PK inhibitor
NCT04095273IAdvanced solid tumors DNA Damage Repair pathway alterations (with ovarian expansion)A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid TumorsView DrugsCalifornia, Maryland, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BAY1895344ATR kinase inhibitor BAY1895344ATR kinase inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT04053673IAdvanced solid tumors (inc expansion)A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid TumorsView DrugsColorado, Florida, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
RBN-2397PARP7 inhibitor
NCT04034238IAdvanced mesothelin+ solid tumorsA Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
LMB-100anti-mesothelin recombinant cytolytic fusion protein RO6927005, anti-mesothelin cytolytic fusion protein LMB-100ADC: anti-mesothelin + Pseudomonas exotoxin (PE)
TofacitinibTasocitinib, CP-690550JAK kinase inhibitor
NCT04007744IAdvanced solid tumors with high MSIA Phase 1 Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
SonidegibLDE225, Smoothened Antagonist LDE225, Erismodegib, OdomzoSmoothened antagonist
NCT03416335IAdvanced solid tumorsA First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsView DrugsIndiana, North Carolina, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DSP-0509toll-like receptor 7 agonist DSP-0509TLR7 agonist and immune cell activator
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT03968406IRecurrent ovarian cancer (amenable to radiation therapy) - without ascitesPhase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT03970382IAdvanced solid tumors (inc expansion)A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid TumorsView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
NeoTCR-P1gene-edited autologous neoantigen-targeted NeoTCR-P1 T cellsAnti-tumor immune response
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03219268IAdvanced solid tumors, including HER2+ cohort (inc expansion)A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic NeoplasmsView DrugsArizona, California, Florida, Illinois, Maryland, Massachusetts, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Margetuximabanti-HER2/c-erbB2 monoclonal antibody, anti-HER2 mAb MGAH22HER2 antagonist
MGD013anti-PD-1/anti-LAG-3 DART protein MGD013, dual-affinity retargeting protein MGD013Blocks LAG-3 and PD-1 inhibition of T cells
NCT03363893IAdvanced solid tumors (inc expansion)A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced MalignanciesView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CT7001CDK7 inhibitor CT7001CDK7 inihibitor

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.